{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:26:39Z","timestamp":1792499199654,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colchicine is a widely used drug to treat inflammatory diseases. Due to its long historical use in medicine, controlled clinical trials have been small and there remains some caution with the use of this drug in patients with co-morbidities. The aim of the study is to systematically examine the side effect profile of colchicine in controlled clinical trials across all published indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with PRISMA methodology. The Cochrane Library, MEDLINE and EMBASE were searched for double-blind controlled trials of oral colchicine in adult patients that reported adverse event data. Meta-analyses were used to determine the relative risk (RR) of adverse events in colchicine users compared to comparator groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4915 studies were initially identified and after exclusions, 35 randomised controlled trials with placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200930) or active comparators (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u20095) were included. The most common diseases studied were gout, liver cirrhosis and pericarditis. There were a total of 8659 pooled participants, 4225 participants were randomised to receive colchicine, 3956 to placebo and 411 to an active comparator. Diarrhoea was reported in 17.9% of colchicine users versus 13.1% in comparator groups (RR 2.4, 95% confidence interval (CI) 1.6, 3.7). Any gastrointestinal event was reported in 17.6% of colchicine users and 13.1% of comparators (RR 1.7, 95% CI 1.3, 2.3). Adverse liver events were reported in 1.9% of colchicine users versus 1.1% in the comparator groups (RR 1.6, 95% CI 0.9, 3.0). Muscle events were reported in 4.2% of colchicine users and 3.3% in the comparator groups (RR 1.3, 95% CI 0.8, 1.9). Haematology events were reported in 0.6% of colchicine users and 0.4% of comparator groups (RR 1.34 (0.64, 2.82). No study reported neuropathy events. Other sensory events were reported in 1.1% of colchicine users and 1.5% of comparator groups (RR 1.4, 95% CI 0.3, 6.7). Infectious events were reported in 0.4% of colchicine users and 2.1% of comparator groups (RR 1.0, 95% CI 0.7, 1.5). No study reported death as an adverse event.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Colchicine increases the rate of diarrhoea and gastrointestinal adverse events but does not increase the rate of liver, sensory, muscle, infectious or haematology adverse events or death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-2120-7","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:05:16Z","timestamp":1581591916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Sarah","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Chih Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"issue":"10","key":"2120_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"2120_CR2","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.30389","volume":"63","author":"RA Terkeltaub","year":"2011","unstructured":"Terkeltaub RA, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226\u201337.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2120_CR3","first-page":"143","volume":"23","author":"TI Evans","year":"1996","unstructured":"Evans TI, et al. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol. 1996;23(1):143\u20138.","journal-title":"J Rheumatol"},{"key":"2120_CR4","volume":"8","author":"S Alabed","year":"2014","unstructured":"Alabed S, et al. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;8:CD010652.","journal-title":"Cochrane Database Syst Rev"},{"issue":"jul21 1","key":"2120_CR5","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A. Liberati","year":"2009","unstructured":"Liberati Alessandro, Altman Douglas G, Tetzlaff Jennifer, Mulrow Cynthia, G\u00f8tzsche Peter C, Ioannidis John PA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"23","key":"2120_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM198612043152304","volume":"315","author":"MM Kaplan","year":"1986","unstructured":"Kaplan MM, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med. 1986;315(23):1448\u201354.","journal-title":"N Engl J Med"},{"issue":"9","key":"2120_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1046\/j.1365-2036.2001.01018.x","volume":"15","author":"PM Battezzati","year":"2001","unstructured":"Battezzati PM, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther. 2001;15(9):1427\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2120_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00042737-200204000-00007","volume":"14","author":"H Cortez-Pinto","year":"2002","unstructured":"Cortez-Pinto H, et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. Eur J Gastroenterol Hepatol. 2002;14(4):377\u201381.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2120_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/0016-5085(79)90018-0","volume":"77","author":"D Kershenobich","year":"1979","unstructured":"Kershenobich D, et al. Treatment of cirrhosis with colchicine. A double-blind randomized trial. Gastroenterology. 1979;77(3):532\u20136.","journal-title":"Gastroenterology"},{"issue":"26","key":"2120_CR10","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJM198806303182602","volume":"318","author":"D Kershenobich","year":"1988","unstructured":"Kershenobich D, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med. 1988;318(26):1709\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"2120_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","volume":"108","author":"R Olsson","year":"1995","unstructured":"Olsson R, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology. 1995;108(4):1199\u2013203.","journal-title":"Gastroenterology"},{"issue":"18","key":"2120_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJM197410312911804","volume":"291","author":"CA Dinarello","year":"1974","unstructured":"Dinarello CA, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291(18):934\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"2120_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/ard.52.11.826","volume":"52","author":"RJ McKendry","year":"1993","unstructured":"McKendry RJ, et al. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis. 1993;52(11):826\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2120_CR14","first-page":"1151","volume":"151","author":"N Roche","year":"1995","unstructured":"Roche N, et al. Nasal response to capsaicin in patients with allergic rhinitis and in healthy volunteers: effect of colchicine. Am J Respir Crit Care Med. 1995;151(4):1151\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2120_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2120_CR16","first-page":"513","volume":"29","author":"S Aran","year":"2011","unstructured":"Aran S, Malekzadeh S, Seifirad S. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol. 2011;29(3):513\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"2120_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ejcts\/ezx422","volume":"53","author":"A Bessissow","year":"2018","unstructured":"Bessissow A, et al. Colchicine for prevention of perioperative atrial fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. Eur J Cardiothorac Surg. 2018;53(5):945\u201351.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"12","key":"2120_CR18","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429\u201332.","journal-title":"J Rheumatol"},{"issue":"5 Pt 1","key":"2120_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1038","volume":"143","author":"AB Cohen","year":"1991","unstructured":"Cohen AB, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of ex-cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;143(5 Pt 1):1038\u201343.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"2120_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1053\/joca.2002.0516","volume":"10","author":"SK Das","year":"2002","unstructured":"Das SK, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartil. 2002;10(4):247\u201352.","journal-title":"Osteoarthr Cartil"},{"issue":"5","key":"2120_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","volume":"19","author":"F Davatchi","year":"2009","unstructured":"Davatchi F, et al. Colchicine versus placebo in Behcet\u2019s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542\u20139.","journal-title":"Mod Rheumatol"},{"issue":"16","key":"2120_CR22","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","volume":"61","author":"S Deftereos","year":"2013","unstructured":"Deftereos S, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2120_CR23","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/dom.13702","volume":"21","author":"AP Demidowich","year":"2019","unstructured":"Demidowich AP, et al. Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. Diabetes Obes Metab. 2019;21(7):1642\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"4 Pt 1","key":"2120_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1164\/ajrccm.156.4.9703012","volume":"156","author":"JE Fish","year":"1997","unstructured":"Fish JE, et al. An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate asthma. National Heart, Lung, and Blood Institute's asthma clinical research network. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1165\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"2120_CR25","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/eurheartj\/ehq319","volume":"31","author":"M Imazio","year":"2010","unstructured":"Imazio M, et al. COlchicine for the prevention of the post-pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31(22):2749\u201354.","journal-title":"Eur Heart J"},{"issue":"7","key":"2120_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","volume":"155","author":"M Imazio","year":"2011","unstructured":"Imazio M, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409\u201314.","journal-title":"Ann Intern Med"},{"issue":"16","key":"2120_CR27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","volume":"369","author":"M Imazio","year":"2013","unstructured":"Imazio M, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"2120_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.2014.11026","volume":"312","author":"M Imazio","year":"2014","unstructured":"Imazio M, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016\u201323.","journal-title":"JAMA"},{"issue":"9936","key":"2120_CR29","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","volume":"383","author":"M Imazio","year":"2014","unstructured":"Imazio M, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232\u20137.","journal-title":"Lancet"},{"issue":"5","key":"2120_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.joca.2018.01.026","volume":"26","author":"YY Leung","year":"2018","unstructured":"Leung YY, et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthr Cartil. 2018;26(5):631\u201340.","journal-title":"Osteoarthr Cartil"},{"issue":"6","key":"2120_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5830\/CVJA-2016-035","volume":"27","author":"JJ Liebenberg","year":"2016","unstructured":"Liebenberg JJ, Dold CJ, Olivier LR. A prospective investigation into the effect of colchicine on tuberculous pericarditis. Cardiovasc J Afr. 2016;27(6):350\u20135.","journal-title":"Cardiovasc J Afr"},{"issue":"8647","key":"2120_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet\u2019s disease. Lancet. 1989;1(8647):1093\u20136.","journal-title":"Lancet"},{"issue":"3","key":"2120_CR33","doi-asserted-by":"publisher","first-page":"E189","DOI":"10.25011\/cim.v33i3.13725","volume":"33","author":"A Pakfetrat","year":"2010","unstructured":"Pakfetrat A, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: a double-blind randomized clinical trial. Clin Invest Med. 2010;33(3):E189\u201395.","journal-title":"Clin Invest Med"},{"issue":"5","key":"2120_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.1780170517","volume":"17","author":"HE Paulus","year":"1974","unstructured":"Paulus HE, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17(5):609\u201314.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2120_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/00007632-198803000-00023","volume":"13","author":"BE Schnebel","year":"1988","unstructured":"Schnebel BE, Simmons JW. The use of oral colchicine for low-back pain. A double-blind study. Spine (Phila Pa 1976). 1988;13(3):354\u20137.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"4","key":"2120_CR36","first-page":"777","volume":"14","author":"P Seideman","year":"1987","unstructured":"Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol. 1987;14(4):777\u20139.","journal-title":"J Rheumatol"},{"key":"2120_CR37","doi-asserted-by":"crossref","unstructured":"Tardif J-C, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u201305.","DOI":"10.1056\/NEJMoa1912388"},{"issue":"4","key":"2120_CR38","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2120_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.7150\/ijms.9165","volume":"11","author":"Y Wang","year":"2014","unstructured":"Wang Y, et al. Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial. Int J Med Sci. 2014;11(9):880\u20135.","journal-title":"Int J Med Sci"},{"issue":"11","key":"2120_CR40","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, et al. A double-blind trial of colchicine in Behcet\u2019s syndrome. Arthritis Rheum. 2001;44(11):2686\u201392.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2120_CR41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/j.1875-9114.1991.tb02629.x","volume":"11","author":"M Levy","year":"1991","unstructured":"Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy. 1991;11(3):196\u2013211.","journal-title":"Pharmacotherapy"},{"issue":"7\u20138","key":"2120_CR42","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1345\/aph.1E593","volume":"39","author":"G Alayli","year":"2005","unstructured":"Alayli G, et al. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7\u20138):1358\u201361.","journal-title":"Ann Pharmacother"},{"issue":"905","key":"2120_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/pmj.77.905.191","volume":"77","author":"I Chattopadhyay","year":"2001","unstructured":"Chattopadhyay I, et al. Colchicine induced rhabdomyolysis. Postgrad Med J. 2001;77(905):191\u20132.","journal-title":"Postgrad Med J"},{"issue":"11","key":"2120_CR44","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1093\/ndt\/12.11.2389","volume":"12","author":"D Ducloux","year":"1997","unstructured":"Ducloux D, et al. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant. 1997;12(11):2389\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2120_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/15563650701779703","volume":"46","author":"G Eleftheriou","year":"2008","unstructured":"Eleftheriou G, et al. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila). 2008;46(9):827\u201330.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"2120_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3349\/ymj.2008.49.1.171","volume":"49","author":"KY Lee","year":"2008","unstructured":"Lee KY, et al. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behcet\u2019s disease. Yonsei Med J. 2008;49(1):171\u20133.","journal-title":"Yonsei Med J"},{"issue":"10","key":"2120_CR47","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/oxfordjournals.ndt.a027096","volume":"11","author":"JJ Montseny","year":"1996","unstructured":"Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. Nephrol Dial Transplant. 1996;11(10):2055\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2120_CR48","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","volume":"24","author":"K Wilbur","year":"2004","unstructured":"Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004;24(12):1784\u201392.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2120_CR49","first-page":"1199","volume":"28","author":"KH Yoon","year":"2001","unstructured":"Yoon KH. Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. J Rheumatol. 2001;28(5):1199\u2013200.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-2120-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T11:42:17Z","timestamp":1722426137000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-2120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2120"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-2120-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a systematic review and meta-analysis, ethical review is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not relevant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SS, KY, KA and PR declare no competing interests. Dr. Dalbeth reports grants and personal fees from AstraZeneca, grants from Amgen, personal fees from Dyve, personal fees from Hengrui, personal fees from Horizon, personal fees from Kowa, personal fees from Abbvie, personal fees from Pfizer, personal fees from Janssen, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}